Stirling Products (STI) announced on the 6/4/2011 that they would be conducting a Share Purchase Plan to raise additional capital. The record date was the 5/4/2011 on which shareholders must own the share to participate in the SPP. The closing date is 2/5/2011. Shares will be issued soon after. A maximum of $15,000 can be purchased by each shareholder at $0.004.
Discount : 0% Liquidity : Poor Profitability : Ok Stability : Poor
*Note: Discount is based on the closing price on the 7 April 2011.
Healthcare group, Stirling Products Limited (STI) is pleased to advise that its Stirling Health division has been successful in winning a 2 plus 2 year contract to represent 3M’s Nexcare range of First Aid, Wound Care and Sports Management product range as well as Futuro product range in Australian pharmacies nationally. Commencing in late January 2011, the Stirling Health pharmacy team will undergo product training with 3M and take responsibility for the promotion of the 3M brands including stock control, positioning, in store training and sales.
Neil Covey, Director of Marketing and Sales for Stirling today stated “Winning this contract with 3M is a major achievement for Stirling Health and represents industry confirmation of the professionalism, quality and value of our national sales team and management. This contract will obviously increase our 2011 revenue and our overall position in the pharmacy market. We look forward to working with 3M over the coming years and growing the markets of their brands”.
The 3M brand representation reinforces the Stirling Health growth strategy in selling unique high quality partner brands together with launching the Company’s own unique brands throughout Australian pharmacies.
http://www.traderdealer.com.au/Fundamentals/sti
Healthcare group, Stirling Products Limited (STI) advises that the Company has conditionally acquired the business and assets of Halcion Pty Ltd, Australia’s fastest growing pathology business.
The acquisition Heads of Agreement provides for payment of a total $3,305,000, with an 80% interest in Halcion to be acquired in consideration of $2,645,000 and to be settled through the issue of 264.5 million shares in the Company. The acquisition of the balance 20% interest held through a co-operative is subject to the co-operative in a meeting in accordance with their constitution agreeing to accept a further 66 million shares in consideration of the balance $660,000.
Mr Con Kostakis, a founder and director of Halcion, stated: “We very much look forward to the next phase of Halcion’s business growth through Stirling Products, as well as for our shareholders to collectively be taking a significant position in a Company that we believe has incredible opportunity, particularly with its e-health TeleMedCare business and pulmonary drug delivery platform. Further, Stirling’s industry interests and national pharmacy representation will complement our growth strategy that we are targeting to double by December 2011.”
Stirling Products Managing Director, Mr Peter Boonen, added: “The Halcion acquisition further expands Stirling as an integrated healthcare group and importantly, will contribute to the Company’s ongoing establishment of significant early revenues. Opportunities within the Australian pathology business sector, which has been undergoing major recent regulatory change, are very limited with the industry being currently dominated by just three major players. Halcion is already well established and profitable within this environment. We look forward to welcoming and working with their dedicated executive team who we have no doubt can also contribute to our overall continued corporate and business development.”
http://www.traderdealer.com.au/Fundamentals/sti
Healthcare group, Stirling Products Limited (STI) advises that its UK trading subsidiary TeleMedCare Limited has issued a market release advising of the award by Buying Solutions, the UK government’s leading centralized procurement agency, of a four year Framework Agreement. The agreement grants TeleMedCare approval to conclude sales directly and to bypass the traditional tender and lengthy procurement process that is generally associated with product sales to government departments, NHS Trusts and other public bodies.
Stirling Products Managing Director, Peter Boonen stated: “It is a great endorsement for the TeleMedCare range of products and services to be approved by the UK Department of Commerce lead procurement agency as a Framework Agreement partner, especially as the award follows the prior establishment of product capability and performance. It is also heartening to see the UK government recognising the efficiencies and savings that e-health solutions can provide to the community and further, being one of the world’s first major active implementers of proven e-health solutions. Ultimately, these early initiatives and the removal of the red tape process for procurement of proven product will see the direct benefit flow through to, not only the chronically ill and aged, but also directly to the taxpayer in due course.”
Buying Solutions is the national procurement partner for all UK public services, established as the Executive Agency of the Office of Government Commerce in the Cabinet Office in the United Kingdom to provide for efficiencies and savings in the public sector procurement process. The primary role of Buying Solutions, who are the only Public Buying Organisation with a legal remit to trade across the whole of the UK public services, is to maximise the value for money obtained by Government departments and other public bodies through the procurement and supply of goods and services. The TeleMedCare framework agreement is for four years and covers the purchase, installation, maintenance, monitoring, coaching and management of its award winning telecare and telehealth e-health solutions to the public sector markets including government departments, NHS Trusts and other public bodies.
http://www.traderdealer.com.au/Fundamentals/sti
Australian healthcare company Stirling Products Limited (STI) is pleased to advise that the Company has been notified that it has been successful in negotiating the acquisition of a 4,310 square metre (46,400 square feet) near new fully equipped and licensed pharmaceutical manufacturing facility in Canada. The facility is being sold to Stirling Products through an administrator of a Canadian listed Company that collapsed as a direct consequence of the Global Financial Crisis. The fully licensed pharmaceutical plant comprises a total 4,310 sq m (46,400 sq ft) of fully equipped and fitted facility that was completed during the course of last year. The facility fit-out of plant, equipment and furnishings is first-class and is fully operational.
Stirling Products Managing Director, Peter Boonen stated: “This sale will complete another key strategic milestone in the global positioning of the Company as well as give the Company total control over a number of its unique products. Further, as a freehold property, this facility will also add to and underpin the Company’s growing asset position.”
Australian healthcare company Stirling Products Limited (STI) advises that the Company and Zodiac Capital Limited, its joint venture partner in pharmaceutical and botanical products, have entered into a final Agreement with Sheiman Ultrasonic Research Foundation Pty Ltd. Under the Agreement, the Stirling/Zodiac joint venture has acquired the rights to commercialise a patented new class of drug inhalation devices that represent a breakthrough platform in drug delivery. Initial validation and independent testing of drug administration using prototype demonstration devices has shown this High Density Aerosol (HDA) technology to be highly efficient and effective in delivering drugs via inhalation. The major benefit of drug administration through the HDA technology is that it promises to provide the same efficacy as drugs taken orally, with far less active drug content which, subject to formal trial validation, should therefore increase drug safety and substantially lessen any side effects. The HDA technology offers a significant opportunity for the Stirling Products joint venture to target a multi-billion revenue market as it leverages its new technology to improve the safety profile of and thereby exclusively use this safer profile of some of the world’s major drugs as they come off patent. This is particularly relevant as in the five year period from 2007 to 2012 over 36 major drugs will come off patent which is expected to lower yearly product sales of the major pharmas in the US by around US$67 billion, and more than double this amount globally.
Stirling Products Limited Managing Director, Mr Peter Boonen, stated: “This HDA technology is absolutely unique in its effectiveness and potential. It will provide a platform for the Company to potentially enhance its own product lines and also to leverage the technology into some of the world’s most valuable drugs that are off-patent or coming off-patent. Through this technology we can effectively have the exclusive rights to, subject to trial validation, the improved version of each of the off-patent drug candidates that we undertake. This potential opportunity for having exclusivity over numerous off-patent blockbuster drugs with the HDA version potentially having their performance and safety profiles enhanced is unmatched in the pharmaceutical industry.”
The key terms of Agreement between the Company, Zodiac Capital and Sheiman Ultrasonic Research Foundation provide for the Company and Zodiac Capital to each pay $250,000 (which payment has been satisfied by the respective issue of shares) and for the Stirling/Zodiac joint venture to provide for all the staged funding costs of the commercialisation process commencing immediately. The first stage over the next 12 months shal be the pre-production development of the first HDA devices which has budgeted costs of circa $600,000. The testing of targeted major off-patent drugs for human use using the HDA inhalation devices is planned to commence in approximately 12 months and is conditional upon the arrangement or provision of a working budget of $5-6 mil ion which is intended to be secured through a series of grants that the Company expects to have in place by that time. The Sheiman Ultrasonic Research Foundation shal receive 35% interest in the gross profits derived from the sale of all HDA devices, 35% of gross profits from the sale of any or all off- patent drugs adapted for use in the new HDA platform, subject to regulatory approvals that may be required for such use, and 5% of the gross sales profits of the Company’s products that are adapted for use through the technology.
Stirling Products (STI) announced on the 29/9/2009 that they would be conducting a Share Purchase Plan to raise additional capital. The record date was the 29/9/2009 on which shareholders must own the share to participate in the SPP. The closing date is 23/10/2009. A maximum of $10,000 can be purchased by each shareholder at $0.01.
Discount : 9.1% Liquidity : Poor Profitability : Ok Stability : Poor
* Note: Discount is based on the closing price on the 29 September 2009.
Stirling Products (STI) announced on the 29/9/2009 that they would be conducting a Share Purchase Plan to raise additional capital. The record date was the 29/9/2009 on which shareholders must own the share to participate in the SPP. The closing date is 23/10/2009. A maximum of $10,000 can be purchased by each shareholder at $0.01.
Discount : 9.1% Liquidity : Poor Profitability : Ok Stability : Poor
* Note: Discount is based on the closing price on the 29 September 2009.
For More Share Purchase Plans go to http://blog.mdsfinancial.com.au/category/share-purchase-plans/
To Buy Shares And Participate in Share Purchase Plans use Trader Dealer http://www.traderdealer.com.au/
Australian healthcare company Stirling Products (STI) is pleased to advise that the key study results of this recent trial confirmed a complete cure of all XDR TB patients supplemented with the botanical immunotherapy product, Immunoxel which demonstrated 100% effectiveness and reduced treatment duration to less than 4 months in all patients as opposed to the general 18-24 months of treatment with standard TB drugs.
Mr. Volodymyr Pylypchuk Director of Ekomed, the product licensor said, “The immune intervention developed by us can not only shorten treatment time and costs drastically but also save countless lives. Our study conducted in Ukraine shows that we can offer a practical solution to the current global TB crisis. We are now planning independent studies in Asia and Africa with the specific aim to use much larger patient population which will support our findings.”
